Kibum Kim
Assistant Professor, Department of Pharmacy Systems, Outcomes and Policy,
Director of Graduate Studies, Department of Pharmacy Systems, Outcomes and Policy
Contact
Address:
833 S WOOD STREET, CHICAGO, ILLINOIS
Office Phone:
Email:
Related Sites:
About Heading link
Overview:
Kibum Kim is an Assistant Professor of Pharmacy Systems, Outcomes, and Policy. He graduated from the University of Illinois at Chicago with his PhD in Pharmacy, with his specialty in pharmacoeconomics and health outcomes research. Prior to working at the University of Illinois at Chicago, he was a research assistant professor of the University of Utah and served as an investigator for comparative effectiveness and market access projects. He also interned at Abbvie, Inc., Takeda Pharmaceuticals, and eMax Health company where he assisted multiple market access and real-world outcome projects. Dr. Kim’s research interest includes contemporary trends in medication utilization, causal inference in health outcome assessment, and model-based cost-effectiveness analysis.
During his career, Dr. Kim has published his research in clinical and economic outcomes of treatment options for diabetes, cardiovascular disorders, and oncology. His recent study activities focus on health technology assessment, clinical utility of diagnostic testing, precision medicine, and the role of bioinformatics in improving healthcare outcomes.
Research Interests:
• Utility of precision medicine and molecular diagnostic testing
• Utilization and outcomes of antiplatelet therapy and anti-coagulation management
• Glycemic control associated with anti-diabetic agent use and concurrent medication to prevent patient from long-term complications
• Resource utilization and healthcare cost across multiple chronic conditions
• Research methods in health outcomes research using real-world databases
• Bioinformatics in health outcomes research
Teaching and Supervision Heading link
Independent Study (PSOP 596), 1/8/2024 – 4/26/2024
PSOP Project (PSOP 597), 1/8/2024 – 4/26/2024
Pharmacoeconomics and Payment (PHAR 565), 8/21/2023 – 12/1/2023
Pharmacoeconomics and Payment (PHAR 565), 8/21/2023 – 12/1/2023
Econmc Eval of Hlthcr Interven (PSOP 573), 8/21/2023 – 12/1/2023
Independent Study (PSOP 596), 8/21/2023 – 12/1/2023
Independent Study (PSOP 596), 6/12/2023 – 8/4/2023
Independent Study (PSOP 596), 1/9/2023 – 4/28/2023
Independent Study (PSOP 596), 8/22/2022 – 12/2/2022
Independent Study (PSOP 596), 1/10/2022 – 4/29/2022
Selected Grants
Economic outcomes of first-line ANG2 vs. CVP in patients with KT for perioperative hemodynamic maintenance., La Jolla Pharmaceutical Company., 6/30/2023 - Present, Obligated Amount: $120000; No Anticipated Amount Set
Type 2 Diabetes Treatment Pathways by Socioeconomic Indicators from Electronic Healthcare Records and Geospatial Analytics, Vahlteich Research Award., 2/15/2023 - 11/18/2022, Obligated Amount: $50000; No Anticipated Amount Set
Exploratory Investigation in the Ubiquity and Outcomes of Non-Medical Medication Switching in Aged Population with Acute Coronary Synderome or Atrial Fibrillation, National Institute on Aging., 5/12/2022 - Present, Obligated Amount: $24; Anticipated Amount: $275000
2022 - 2023 Institute for Clinical and Economic Review Consulting Agreement, Institute for Clinical and Economic Review., 1/1/2022 - 12/30/2025, Obligated Amount: $520000; Anticipated Amount: $520000
Cost-Effectiveness and Budget Impact of Artificial Intelligence-driven Risk-Stratification in Patients with Diabetic Kidney Disease (DKD), University of Utah., 10/1/2021 - 6/30/2023, Obligated Amount: $247482; Anticipated Amount: $247482
Leveraging machine learning to enhance electronic health record data for drug effectiveness and safety research in depression, .., 6/1/2021 - 5/31/2023, Obligated Amount: $165000; Anticipated Amount: $165000
Preliminary assessment of the alteration of oral antiplatelet agent regimens in patients with acute coronary syndrome, Greater Plains Collaborative., 11/1/2019 - 2/22/2021, Obligated Amount: $10000; Anticipated Amount: $10000
Selected Publications
Parab, Ashwini Z, Kong, Angela, Lee, Todd A, Kim, Kibum, Nutescu, Edith A, Malecki, Kristen C, Hoskins, Kent F, Calip, Gregory S. (2024). Socioecologic Factors and Racial Differences in Breast Cancer Multigene Prognostic Scores in US Women. JAMA Network Open, 7, (4), e244862. doi:10.1001/jamanetworkopen.2024.4862.
Lau, Anson TC, DiDomenico, Robert J, Kim, Kibum. (2024). Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States. International Journal of Cardiology, 398, 131598. doi:10.1016/j.ijcard.2023.131598.
Wynn, Emma, Biskupiak, Joseph, Kim, Kibum, Munger, Mark A. (2024). Pregabalin Does Not Increase Risk of Heart Failure Exacerbation in Patients With Pre-existing Heart Failure. Annals of Pharmacotherapy, 58, (1), 15-20. doi:10.1177/10600280231165259.
Radwanski, Przemyslaw, KIM, KIBUM, Kim, Sodam, Katana, Margaret, Munger, Mark A. (2023). Abstract 12880: Riluzole Significantly Lowers Heart Failure Incidence. Circulation, 148, (Suppl_1), a12880-a12880. doi:10.1161/circ.148.suppl_1.12880.
Chao, Darin, Zhu, Julia, Tak, Casey, Kim, Kibum, Henkels, Rebecca, Munger, Mark A. (2023). US Departments of Pharmacy practice single terminal‐degree tenure‐track scholarly activity. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 6, (10), 1091-1096. doi:10.1002/jac5.1847.
Nowakowski, Grzegorz S, Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Peters, Anthea, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Sabatelli, Lorenzo, Waltl, Eva E, Winderlich, Mark, Sporchia, Andrea, Kurukulasuriya, Nuwan C, Cordoba, Raul, Hess, Georg, Salles, Gilles. (2023). Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma. Annals of Hematology, 102, (9), 2643-2644. doi:10.1007/s00277-023-05321-3.
Nowakowski, Grzegorz S, Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Peters, Anthea, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Sabatelli, Lorenzo, Waltl, Eva E, Winderlich, Mark, Sporchia, Andrea, Kurukulasuriya, Nuwan C, Cordoba, Raul, Hess, Georg, Salles, Gilles. (2023). RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. Annals of Hematology, 102, (7), 1773-1787. doi:10.1007/s00277-023-05196-4.
Zolekar, A, Kong, A, Lee, TA, Kim, K, Nutescu, EA, Calip, GS. (2023). EPH77 Association of Socioeconomic Position and Racial Disparities in Multigene Prognostic Score Measuring Breast Cancer Recurrence Risk. Value in Health, 26, (6), s177-s178. doi:10.1016/j.jval.2023.03.959.
Shah, K, Kim, K, Lien, H, Atlas, SJ, Moradi, A, Beaudoin, F, Touchette, DR. (2023). EE8 Cost-Effectiveness of Long-Term Medication Therapy for Obesity Management. Value in Health, 26, (6), s61. doi:10.1016/j.jval.2023.03.316.
Education
Degrees:
PhD, University of Illinois at Chicago, United States, 2017
MSc, Catholic University of Daegu, Korea, Republic of, 2008
BPharm, Catholic University of Daegu, Korea, Republic of, 2006
Postgraduate Training:
Research Fellow, University of Utah, United States, 2018